The composition of COVID-19 vaccines developed by the Gamaleya Center, including those for adolescents, excludes the developoment of multisystem inflammatory syndrome after vaccination. This is reported by TASS with reference to Aleksander Ginzburg, the director of the center.
“No compounds that interact directly with the half-receptors triggering inflammatory reactions are introduced into the body with the vaccine, so there is no risk of the development of multisystem inflammatory syndrome in persons vaccinated with the Gamaleya Center products. Another distinguishing feature of our vaccine is that we purify it very well,” Ginzburg said.
According to him, 100,000 doses of Sputnik M for teenagers are to be released into civil circulation this week.
Specialists from the US Centers for Disease Control and Prevention had previously published an article in Lancet magazine, which says that after vaccination against coronavirus some adolescents may develop a multisystem inflammatory syndrome affecting several body systems simultaneously. The study analyzed reports of side effects of vaccination from December 14, 2020 to August 31, 2021. During this time, more than 21 million adolescents aged 12-20 were vaccinated. 21 teenagers suffered multisystem inflammatory syndrome.
At the same time, most of them were found to have traces of prior coronavirus infection, which may be associated with the development of the syndrome. However, no signs of the disease were found in six other subjects. The study was conducted in the USA. The publication does not state which vaccines were administered to the adolescents in the sample.
Kazakhstan became the first foreign country to approve Sputnik M vaccine.
